Brief: Prescient Therapeutics Secures EU Orphan Drug Designation For PTX-100
18/11/2025 22:04
Nov 19 (Reuters) - Prescient Therapeutics Ltd PTX.AX: PTX SECURES EU ORPHAN DRUG DESIGNATION FOR PTX-100 IN CTCL Further company coverage: PTX.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Prescient Therapeutics
See all newsAustralia's Prescient Therapeutics falls on discounted share placement
Brief: Prescient Therapeutics Raises A$4.8 Million Via SPP, A$1.2 Million In Placement
Brief: Prescient Therapeutics Says Trading Halt Requested
Australia's Prescient Therapeutics hits near 2-month low on discounted raise
Brief: Prescient Therapeutics Secures EU Authorisation To Commence PTX-100 Clinical Trial